Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular and fibrotic changes in the skin and in internal organs. Endothelin-l (ET-l) is a peptide that has a role in promoting both vascular injury and the fibrotic process in SSc; indeed, patients with systemic sclerosis have higher levels of ET-l compared with healthy subjects. Moreover, ET-l enhances expression of pro-inflammatory cytokines in animal model. Bosentan is a dual endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension and digital ulcers in scleroderma patients. In animal models and in vitro models, after treatment with Bosentan, a significant reduction of cytokine (TNFa, IFNy,IL-8, IL-4) levels was observed. The aim of the study is to verify whether Bosentan treatment in SSc patients can reduce circulating cytokines levels. We enrolled 10 patients affected by SSc with digital ulcers and/or pulmonary hypertension, treated with Bosentan 125 mg twice daily. Patients were tested for cytokines and ET-l level before treatment and after 12 months. The cytokines tested were IL-I0, IL-2, IL-4, IL-5, IL-6, IL-8, GM-CSF, IFN-y and TNF. Levels of ET-l, IL-I0, IL-4, IL-5, GM-CSF and TNFa did not show consistent modification during treatment with Bosentan in respect to baseline, while IL-2, IL-6, IL-8 and IFN-y were significantly decreased. Bosentan significantly reduced IL-2, IL-6, IL-8 and IFN-y levels in SSc patients, probably slowing progression to fibrosis and vascular damage. This is the first report showing a decrease of profibrotic and proinflammatory cytokines levels in humans during treatment with Bosentan.
Systemic sclerosis is an autoimmune connective tissue disease characterized by cutaneous and visceral fibrosis and widespread vascular pathology (I). The most common and evident expression is Raynaud's phenomenon, an abnormal reactivity of blood vessels to cold and other stimuli (2) . The pre-existence of Raynaud's phenomenon, before the development of skin thickening, indicates that micro vascular pathology is an important primary event in the pathogenesis of scleroderma (3), where microvasculature presents not only a functional abnormality, but also structural change including intimal proliferation and obstruction (4).
The mechanism of vascular damage has been under investigation; the most probable hypothesis is a multifactorial condition with subsequent loss of normal vasodilatory mediators and increased release of Endothelin I (ET I).
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Recently, many publications have shown that ETI has a key role also in inflammatory cascade. ETl, probably, induce increase of expression of other pro-inflammatory molecules.
Bosentan is a dual endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension and digital ulcers in scleroderma patients. In animal models and in vitro models, after treatment with Bosentan, a significant reduction of cytokines levels was observed.
The aim of the study is to verify whether Bosentan treatment can reduce circulating cytokine levels in scleroderma patients.
MATERIALS AND METHODS
Ten patients affected by SSc were enrolled. Five patients had diffuse subset disease, 5 patients had limited subset disease according to Le Roy criteria (6), mean age was 53 years, mean disease duration was 78 months. They all had digital ulcers, and were therefore treated with Bosentan 125 mg twice daily. All patients gave informed consent to be tested for cytokines and ET-I level before treatment and after 12 months. Patients were treated with Bosentan; 3 of them were taking low, stable doses of prednisone (5 mg daily) started more than 6 months before Bosentan, and never stopped until the end of the study. Three patients were also receiving methotrexate for their skin involvement, at a stable dose started more than 6 months before Bosentan treatment. No changes in therapy were made for all the period of observation Cytokines were evaluated by Bio-Plex Protein array System using human multiplex cytokine detection kit ( BIO-RAD and Panomics, USA). Serum levels of cytokines and chemokines, including IL-lO, IL-2, IL-4, IL-5, IL-6, IL-8, GM-CSF, IFN-y,TNFu, were measured using a beadbased immunofluorescence assay (Luminex, TX, USA) with multiplex cytokine reagents (Millipore, MA,USA).
Briefly, a sandwich immunoassay-based protein array system (MilliplexTM, human cytokine-high sensitivity), containing dyed microspheres conjugated with a monoclonal antibody specific for a target protein was used in this assay. Serum samples were thawed and run in duplicates. Antibody-coupled beads were incubated with the plasma sample (antigen) and were then incubated with biotinylated detection antibody; the final incubation was performed with streptavidin-phycoerythrin. A broad sensitivity range of standards, ranging between 0.03 and 2000 pg/ml, was used to enable the quantification of a dynamic wide range of cytokine concentrations and provide the greatest sensitivity. The captured beadcomplexes were evaluated with the Bio-Plex array reader (Bio-Rad Laboratories, Hercules, CA). The instrument uses Luminex fluorescent bead-based technology characterized by a flow-based dual laser detector with real-time digital signal processing; this facilitates the analysis of up to 100 different families of colour-coded polystyrene beads and allows multiple measurements of the sample ensuring the effective quantification of cytokines. ET-I concentrations were evaluated by ELISA (Phoenix Pharmaceuticals). Statistical analysis was performed with Wilcoxon Signed Ranks Test.
RESULTS
After 3 and 6 months serum cytokine levels were reduced, but none of them was significant. After 12 months, levels of ET-l, IL-I0, IL-4, IL-5, GM-CSF and TNFa ?did not show consistent modification in respect to baseline.
The other cytokines, IL-2, IL-6, IL-8 and IFN-y, were significantly decreased, as reported in Table I and Fig. 1 .
DISCUSSION
Several studies have shown the essential role of ET-l in fibrosis process as downstream regulators The correlation coefficient (r) baseline versus 12 months, is very close to 1 and this means that a direct proportionality exists between two groups ofnumbers. The drug-action reduces the cytokine concentration in proportionate manner. or co-factors of TGF beta signalling (7) . As already described, in our study ETl levels did not show significant variation after Bosentan treatment (8) . Our results show that Bosentan significantly reduces IL-2, IL-6, IL-8 and IFN-y levels in SSc patients . IL-2 stimulates the growth, differentiation and survival of antigen-selected cytotoxic T cells. IL-6 is responsible for many different processes and is a critical component in the communication between myocytes and fibroblasts (9) . IL-6 is one of the most important mediators of the acute phase response, induces intracellular signalling cascade that gives rise to inflammatory cytokine production and also plays an important role in the promotion of fibrosis, therefore probably being a key cytokine in the pathogenesis of SSc. Kadono and colI. demonstrated that basal production of both IL-6 and IL-8 was significantly increased in scleroderma fibroblasts compared with controls (10) . In a recent study, performed to determine the serum levels of different biomarkers in patients with SSc and secondary PAH and to compare them with those of healthy control subjects to define their potential role as predictors of PAH, IL-8 was higher in the study group respect to controls (p=0.0364)( 11). In SSc, it was established that there are specific subpopulations of cells, particularly the subpopulation of y/8 T cells, which present a Th 1 phenotype with high secretion of IFN-y (12) . Other Authors have demonstrated the production of IFN-y by PBMCs from patients with SSc (13) (14) . As of today, ETl seems to have a key role also in inflammation cascade . Stopping the ETI pathological actions could represent a new approach for slowing down the pathology progression . Further investigation are needed, but this is the first report showing a decrease of profibrotic and proinflammatory cytokines levels in humans during treatment with Bosentan.
